EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation

Sandra Schrenk iD, Chhiring Sherpa iD, Lindsay J Bischoff iD, Yuqi Cai iD, Elisa Boscolo iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2025-12 · 45 (12) · 2243-2260

DOI: 10.1161/atvbaha.125.323387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025-12. Verfasst von Sandra Schrenk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH (S.S., C.S., L.J.B., Y.C., E.B.). Hauptthemen laut MEDLINE: Receptor, TIE-2, Vascular Malformations, Mutation, Endothelial Cells. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Venous malformations (VMs) are developmental defects of the vasculature characterized by tremendously enlarged and dysfunctional veins. Gain-of-function somatic mutations in TIE2 (endothelial tyrosine kinase receptor) have been identified as the leading driver of VM pathogenesis. The aim of this study was to determine whether the aberrant venous lumen expansion is caused by recruitment of wild-type (WT) endothelial cells (EC) to the lesion or by TIE2-mutant EC clonal expansion. METHODS: To investigate the contribution of TIE2-mutant EC and WT EC to the aberrant venous lumen expansion, we used a xenograft murine model of VM generated with a combination of TIE2-mutant EC and WT EC. To perform longitudinal studies, we used a 3-dimensional fibrin gel lumen formation assay and a migration assay, both using WT EC in competition or confrontation with TIE2-mutant EC. To investigate the mechanisms implicated in VM lumen expansion, we used RNA-sequencing and short-hairpin RNA silencing in the TIE2-mutant EC. RESULTS: We demonstrate here that in the VM xenograft model, the aberrant blood vessels were lined almost exclusively by TIE2-mutant EC, and WT EC were rarely found. Functionally, the TIE2-mutant EC exerted a competitive advantage over WT EC by inhibiting WT EC sprouting. In line with these findings, TIE2-mutant EC promoted repulsion of WT EC. Short-hairpin RNA-mediated silencing of Sema (Semaphorin) 3A or Sema3F in TIE2-mutant EC rescued this chemorepellent phenotype and restored the ability of WT EC to migrate, sprout, and form lumens. Furthermore, knockdown of Sema3A or Sema3F in TIE2-mutant EC normalized the blood vessel size in vivo. CONCLUSIONS: Our results demonstrate that WT EC are not recruited to the aberrant veins, suggesting that VM pathogenesis is fueled by clonal expansion of TIE2-mutant EC. Mechanistically, we show that Sema3A and Sema3F are overexpressed in TIE2-mutant EC and play a crucial role in the pathological vascular lumen expansion in VM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, TIE-2Vascular MalformationsMutationEndothelial CellsVeinsSemaphorin-3AAnimalsHumansCell MovementDisease Models, AnimalPhenotypeSignal TransductionMiceCells, CulturedCell ProliferationHuman Umbilical Vein Endothelial CellsNeovascularization, Pathologic

Stichwörter der Autor:innen

NeuropilinsSemaphorinsendothelial cellsreceptor, TIE-2vascular malformations

Substanzen

Receptor, TIE-2Semaphorin-3ATEK protein, humanTek protein, mouseSEMA3A protein, human

Autor:innen und Institutionen

  • Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, OH (S.S., C.S., L.J.B., Y.C., E.B.).
  • Department of Pediatrics (S.S., E.B.), University of Cincinnati College of Medicine, OH.
  • Department of Cancer Biology (L.J.B.), University of Cincinnati College of Medicine, OH.

ORCID-Profile: Sandra Schrenk, Chhiring Sherpa, Lindsay J Bischoff, Yuqi Cai, Elisa Boscolo

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Schrenk, S., Sherpa, C., Bischoff, L. J., Cai, Y., & Boscolo, E. (2025). Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation. Arteriosclerosis, Thrombosis, and Vascular Biology, 45(12), 2243-2260. https://doi.org/10.1161/atvbaha.125.323387

Vancouver

Schrenk S, Sherpa C, Bischoff LJ, Cai Y, Boscolo E. Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025;45(12):2243-2260. doi:10.1161/atvbaha.125.323387

BibTeX
@article{Schrenk2025,
  author = {Schrenk, Sandra and Sherpa, Chhiring and Bischoff, Lindsay J and Cai, Yuqi and Boscolo, Elisa},
  title = {Semaphorin 3A and 3F Promote Lumen Expansion in TIE2-Mutated Venous Malformation},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2025},
  volume = {45},
  number = {12},
  pages = {2243--2260},
  doi = {10.1161/atvbaha.125.323387}
}
Kostenlos starten →